Loading
A phase 3 trial of TAR-210 and Gemcitabine in bladder & urothelial cancer, run by Janssen Research & Development, LLC, now recruiting.
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer is a phase 3 interventional study registered as NCT06319820 by Janssen Research & Development, LLC, with 641 participants planned, started 2024-04-18 and due to reach its primary completion in 2028-06-28. Interventions recorded: TAR-210, Gemcitabine and MMC.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Non-muscle-invasive bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares TAR-210, Non-muscle-invasive bladder cancer, Johnson & Johnson, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Johnson & Johnson, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/